The Senior Leadership is the central decision-making and internal advisory body, with the goal to encourage research productivity, promote interaction and collaboration, and take maximum advantage of institutional strengths and unique scientific opportunities. As Director, Dr. Donald Trump has broad authority over all aspects of the Cancer Center, and he is the ultimate visionary and decision-maker for scientific and administrative matters. The Deputy Director and Associate Directors are accomplished, productive scientists, having served on study sections, as well as important national advisory boards. The Senior Leaders are: Dr. Donald Trump, Director (recruited in 2002, appointed Director in 2007);Dr. Candace Johnson, Deputy Director (recruited in 2002, appointed in 2008);Dr. Alex Adjei, Associate Director for Clinical Research (2006);Dr. Andrei Gudkov, Associate Director for Basic Research (2007);Dr. Richard Hershberger, Chief Academic Officer (2011);Dr. James Marshall, Associate Director of Population Sciences Research (2002);Dr. James Mohler, Associate Director for Translational Research (recruited 2003, appointed 2008);and Brian Springer, Associate Director for Administration (2011). Each of the Senior Leaders also plays a pivotal role in CCSG Programs, Shared Resources, and/or administrative services. This team works closely and collaboratively to integrate RPCI research efforts, promote transdisciplinary interaction and collaboration, and set strategic direction and priorities. The leaders place specific emphasis on moving basic science research through the translational pipeline using internal and external mechanisms, as well as research focused within the RPCI catchment area. The leadership team builds and develops training and education programs to prepare future generations of cancer scientists. Over this funding cycle (2008 to 2013) and in accordance with the strategic plan, the Senior Leadership team worked together to recruit more than 137 cancer investigators and clinicians, of whom 51 are CCSG members. The group's emphasis on developing outstanding basic, translational, clinical, population science led to a 17% increase in peer-reviewed funding from $60.5 to $70.8 million. Efforts for development of investigator-initiated trials, resulted in an increase in institutional intervention accrual from 546 (2008) to 620 (2012), with institutional accrual rising from 60.3% to 71.3% of overall interventional accrual.

Public Health Relevance

RPCI Senior Leadership works effectively to manage the Cancer Center Support Grant, establish the overall direction and plan strategically for the Institute. The leaders are responsible for clinical, basic and translational research efforts across all programmatic areas seeking to understand, prevent and cure cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Ciamporcero, Eric; Miles, Kiersten Marie; Adelaiye, Remi et al. (2015) Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther 14:101-10
Ma, Yingyu; Hu, Qiang; Luo, Wei et al. (2015) 1?,25(OH)2D3 differentially regulates miRNA expression in human bladder cancer cells. J Steroid Biochem Mol Biol 148:166-71
Shen, Li; Sundstedt, Anette; Ciesielski, Michael et al. (2015) Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol Res 3:136-48
Adelaiye, Remi; Ciamporcero, Eric; Miles, Kiersten Marie et al. (2015) Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Mol Cancer Ther 14:513-22
Uekusa, Shota; Kawashima, Hiroyuki; Sugito, Kiminobu et al. (2014) Nr4a3, a possibile oncogenic factor for neuroblastoma associated with CpGi methylation within the third exon. Int J Oncol 44:1669-77
Ambrosone, Christine B; Zirpoli, Gary; Ruszczyk, Melanie et al. (2014) Parity and breastfeeding among African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women's Circle of Health Study. Cancer Causes Control 25:259-65
Röhm, Marc; Grimm, Melissa J; D'Auria, Anthony C et al. (2014) NADPH oxidase promotes neutrophil extracellular trap formation in pulmonary aspergillosis. Infect Immun 82:1766-77
Rohrbach, Daniel J; Muffoletto, Daniel; Huihui, Jonathan et al. (2014) Preoperative mapping of nonmelanoma skin cancer using spatial frequency domain and ultrasound imaging. Acad Radiol 21:263-70
Ambrosone, Christine B; Young, Allyson C; Sucheston, Lara E et al. (2014) Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry. Oncotarget 5:237-48
O'Brien, Shalana; Golubovskaya, Vita M; Conroy, Jeffrey et al. (2014) FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics. Oncotarget 5:7945-59

Showing the most recent 10 out of 517 publications